Strong operating performance exceeds guidance with Group sales up 11.8%1 driven by Specialty Care and Core Operating Margin improvement despite Cabometyx® launch investments
Acquisition of Onivyde® and new Primary Care products expected to close during the first half of 2017
PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced financial results for the full year 2016.
